Lipocine Inc (NASDAQ:LPCN) shares reached a new 52-week low on Thursday . The company traded as low as $1.87 and last traded at $3.46, with a volume of 1910600 shares. The stock had previously closed at $3.42.
A number of research analysts have weighed in on LPCN shares. Ladenburg Thalmann Financial Services reissued a “buy” rating and issued a $11.00 target price on shares of Lipocine in a research note on Thursday. Canaccord Genuity reissued a “hold” rating and issued a $2.00 target price (down from $11.00) on shares of Lipocine in a research note on Tuesday. Finally, HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Lipocine in a research note on Friday, December 8th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company. The company has a consensus rating of “Hold” and a consensus price target of $13.50.
The company has a market capitalization of $36.25, a P/E ratio of -1.78 and a beta of 0.11.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. acquired a new stake in shares of Lipocine during the 2nd quarter worth approximately $300,000. Federated Investors Inc. PA increased its holdings in shares of Lipocine by 9.2% during the 2nd quarter. Federated Investors Inc. PA now owns 88,083 shares of the specialty pharmaceutical company’s stock worth $354,000 after buying an additional 7,429 shares during the last quarter. P.A.W. Capital Corp acquired a new stake in shares of Lipocine during the 3rd quarter worth approximately $397,000. Ameriprise Financial Inc. increased its holdings in shares of Lipocine by 18.2% during the 2nd quarter. Ameriprise Financial Inc. now owns 155,600 shares of the specialty pharmaceutical company’s stock worth $626,000 after buying an additional 24,000 shares during the last quarter. Finally, Vanguard Group Inc. increased its holdings in shares of Lipocine by 39.7% during the 2nd quarter. Vanguard Group Inc. now owns 546,027 shares of the specialty pharmaceutical company’s stock worth $2,195,000 after buying an additional 155,110 shares during the last quarter. 22.06% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This piece of content was originally posted by Stock Observer and is owned by of Stock Observer. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece of content can be viewed at https://www.thestockobserver.com/2018/01/13/lipocine-lpcn-reaches-new-12-month-low-at-1-87.html.
Lipocine Inc is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for bioavailable drugs.
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.